Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going

Jun 12 2019

• By Mandy Jackson

Stack-100 bills — ADC Therapeutics has raised $531m since 2011 • Source: Shutterstock

Related Content

So Far, Still So Good For Seattle Genetics/Astellas’ Bladder Cancer ADC

Jun 04 2019

Lung Cancer, Conjugates Emerge As Key Asia Company Themes

Jun 04 2019

Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL

Jun 11 2019

ADC Therapeutics Raises $105m To Reach Pivotal Studies

Oct 18 2016

$80m Windfall Will Push 7 ADC Drug Candidates Into Clinic Within Two Years

Sep 03 2015

Private equity player Celtic bankrolls new Swiss antibody-drug conjugate company

Mar 26 2012

Related Companies

ADC Therapeutics SA

Roche Holding AG

Daiichi Sankyo Co., Ltd.

AstraZeneca PLC

Seagen Inc.

Astellas Pharma, Inc.

Additional Topics

Financing Business Strategies Innovation Companies Commercial Cancer BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.